Por qué es un doctor de primer nivel
Miss Christina Choy is an experienced oncoplastic breast surgeon based in London, with a specialist expertise in one stop rapid assessment for various breast symptoms and lumps, family history risk assessment and genetic testing, breast screening and counselling, state of the arts management for both benign breast disease and breast cancer. She works at HCA hospitals in London with a group of dedicated multidisciplinary team members to provide holistic personal care with updated and cutting-edge management approaches for breast management. She is a trustee for Breast Cancer Hope Charity which promotes breast cancer research for improvement of breast cancer awareness and disease treatment.
Miss Christina Choy qualified from the Medical School of the University of Sydney in 1986 and undertook her postgraduate training in surgery and has worked in various major centres in Australia, Hong Kong and the UK, including The Royal Marsden Hospital and St Bartholomew’s Hospital. She worked as consultant breast surgeon in the NHS previously and was Lead for the Breast Service at the Homerton University Hospital. She has worked in the private sector since 2003. From January 2017 she has worked exclusively for HCA private hospitals including the London Breast Institute at the Princess Grace Hospital, the Harley Street Clinic, the Portland Hospital for women and the new HCA specialist unit at the Chiswick Outpatient and Diagnostic Centre.
Miss Choy is actively involved in research and has worked in conjunction with the pathology department at St Bartholomew's Hospital on a study of the gene arrays and demographic data of young women, particularly Afro-Caribbean women and other ethnic groups, presenting with breast cancer. Other projects that she is involved in include research into barriers to women accessing early diagnosis and treatment for breast cancer in various ethnic groups (in conjunction with King's College Hospital, recently presented in Parliament for Black Afro-Caribbean and Ethnic Minority Group, BAEM), the development of a 23 hours model for early discharge after breast cancer surgery and an audit to determine if sentinel node of highest isotope count can be the predictor of nodal status in breast cancer.